Pendopharm
Pendopharm is the branded specialty pharmaceutical division of Montreal-based Pharmascience Inc., commercializing 40+ specialty prescription drugs, pediatric formulations, and consumer health products across gastroenterology, orthopedics, neurology, and cardiology in Canada through exclusive licensing partnerships with international pharmaceutical innovators.
- Company typePrivate
- Founded2010
- HeadquartersMontreal, Canada
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pendopharm does
Pendopharm is the branded specialty pharmaceutical division of Pharmascience Inc., a privately held Canadian pharmaceutical company founded in 1983 and headquartered in Montreal, Quebec. Established in 2010 as Pharmascience's specialty-branded arm, Pendopharm develops, in-licenses, and commercializes 40+ specialty pharmaceutical products across four therapeutic areas: gastroenterology, sports medicine and orthopedics, neurology, and cardiology. The product portfolio includes branded specialty prescription drugs (Yorvipath for hypoparathyroidism, GLATECT for multiple sclerosis, Cingal/Monovisc/Orthovisc/SportVis for osteoarthritis and tendon/ligament pain), first-in-Canada pediatric formulations (prpdp-AMLODIPINE, prpdp-LevETIRAcetam), gastrointestinal therapies (Octasa, ELEVIEW), and consumer health products (PHARIXIA, PrPERICHLOR).
Pendopharm's business model is built on exclusive distribution and licensing partnerships with international pharmaceutical innovators — including Ascendis Pharma, Anika Therapeutics, KalVista Pharmaceuticals, Neuraxpharm, Cosmo Pharmaceuticals, and Synthon — under which Pendopharm manages Health Canada regulatory approval and Canadian commercialization in exchange for distribution rights. Revenue derives from product sales through Canadian pharmaceutical wholesalers, specialty pharmacy channels, and direct institutional sales, with reimbursement secured via all major provincial drug formularies (Ontario, Alberta, Quebec, Saskatchewan, Manitoba, New Brunswick, British Columbia) and private insurers. Patient support programs such as the Ally Patient Support Program provide injection training, reimbursement assistance, and financial support.
The company leverages its parent Pharmascience's GMP manufacturing infrastructure and 1,500-employee operational base, while operating a dedicated specialty field force targeting endocrinologists, neurologists, gastroenterologists, sports medicine specialists, and other healthcare professionals. Customer engagement runs through medical information services, continuing education programs (webinars, tele-expertise), and healthcare professional communications, with no disclosed direct-to-consumer channels. Pricing is not publicly disclosed; products are reimbursed under public and private drug plans rather than sold on a transactional consumer basis.
Pendopharm firmographics
Firmographics- Name
- Pendopharm
- Legal name
- PENDOPHARM, Division of Pharmascience Inc.
- Website
- https://pendopharm.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Pendopharm is the branded specialty pharmaceutical division of Montreal-based Pharmascience Inc., commercializing 40+ specialty prescription drugs, pediatric formulations, and consumer health products across gastroenterology, orthopedics, neurology, and cardiology in Canada through exclusive licensing partnerships with international pharmaceutical innovators.
- Ownership category
- akta.pro rank
Pendopharm industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Oral Care Products (Toothpaste, Mouthwash, Dental Floss, Whitening) (CRADAMAA)
Keywords
Where Pendopharm is headquartered
LocationHeadquarters
- HQ city
- Montreal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Pendopharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Specialty Pharmaceutical Product Sales: Pendopharm generates revenue through commercialization of specialty prescription medicines and consumer brands in Canada. The company develops, in-licenses and commercializes innovative products across four core therapeutic areas.
- Exclusive Distribution Agreements: Pendopharm enters into exclusive distribution agreements with international pharmaceutical companies to manage regulatory approval and commercialization of products in Canada, receiving distribution rights in exchange for local market expertise and commercialization capabilities.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Pendopharm product offering
Product offeringCore offering
Pendopharm develops, in-licenses and commercializes specialty pharmaceutical products in Canada across four core therapeutic areas: gastroenterology, sports medicine & orthopedics, neurology, and cardiology. Its portfolio of more than 40 specialty products includes branded prescription drugs (Yorvipath, GLATECT, Octasa, IBAVYR), viscosupplementation treatments (Cingal, Monovisc, Orthovisc, SportVis), endoscopic procedural products (ELEVIEW), pediatric formulations, and consumer oral-care brands. The company secures exclusive Canadian distribution rights from international innovators and manages regulatory approval, market access, and commercialization.
Product overview
Pendopharm is a Canadian specialty pharmaceutical company offering a diversified portfolio of specialty prescription drugs, pediatric formulations, and consumer health products. The company's specialty products span four core therapeutic areas: gastroenterology (including Octasa® for IBD and ELEVIEW™ for endoscopic procedures), sports medicine & orthopedics (including SportVis™, Cingal®, Monovisc®, and Orthovisc® for hyaluronic acid-based treatments), neurology (including GLATECT™ for MS and prpdp-LevETIRAcetam for epilepsy), and cardiology (including Yorvipath® for hypoparathyroidism). Pendopharm also focuses on unmet medical needs through pediatric formulations (prpdp-AMLODIPINE, prpdp-LevETIRAcetam) and consumer health products (PHARIXIA, PrPERICHLOR®). The company operates primarily through distribution partnerships with international pharmaceutical companies to commercialize innovative medicines in Canada.
Differentiator
Problem solved
Functional benefit
Brands
- PrPERICHLOR: Alcohol-free gingivitis oral rinse for professional treatment of moderate to severe gingivitis
- Octasa
- GLATECT
- SportVis
- prpdp-AMLODIPINE
- ELEVIEW
Products and services
- Yorvipath® (palopegteriparatide injection) Parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism in adults, developed by Ascendis Pharma and commercialized in Canada by Pendopharm under an exclusive distribution agreement.
- Buccolam® Pediatric epilepsy treatment for buccal administration, commercialized in Canada by Pendopharm under an exclusive distribution agreement with Neuraxpharm.
- Sebetralstat Investigational oral on-demand therapy for Hereditary Angioedema (HAE), distributed in Canada under exclusive agreement with KalVista Pharmaceuticals.
- Cingal® / Monovisc® / Orthovisc® Hyaluronic acid-based viscosupplementation products for the treatment of osteoarthritis pain. Cingal is a next-generation single-injection non-opioid treatment; Monovisc and Orthovisc are single-injection viscosupplementation therapies.
- Octasa® (oral mesalamine)
Quantifiable outcome
- More than 40 specialty products across multiple therapeutic areas
- +1 more outcomes
Companies that use Pendopharm
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles3 records
Pendopharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pendopharm partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- NeuraxpharmcoreExclusive distribution agreement for Buccolam in Canada. Buccolam received Health Canada approval and was commercialized in February 2026. Neuraxpharm is a pharmaceutical company specializing in CNS treatments.
- KalVista PharmaceuticalscoreExclusive distribution agreement for sebetralstat, an investigational oral therapy for Hereditary Angioedema (HAE). Under regulatory review in multiple countries, sebetralstat would become the first oral on-demand treatment for HAE in Canada. Financial terms not disclosed.
- Ascendis Pharma A/ScoreExclusive distribution agreement where Pendopharm is responsible for regulatory approval and commercialization of TransCon PTH (palopegteriparatide) for chronic hypoparathyroidism in Canada. Yorvipath received Health Canada approval in February 2026. Ascendis is a global biopharma company headquartered in Copenhagen, Denmark (NASDAQ: ASND).
- Anika Therapeutics Inc.coreRenewal of exclusive distribution agreement for Cingal, Monovisc, and Orthovisc through end of 2030. Partnership since 2012. Anika is a global joint preservation company (NASDAQ: ANIK) providing hyaluronic acid-based therapeutic solutions. Cingal is a next-generation non-opioid treatment for osteoarthritis pain.
- Cosmo PharmaceuticalsmajorDistribution partnership for ELEVIEW, the first all-in-one submucosal injectable composition for endoscopic resection procedures. Cosmo is a specialty pharma company focused on GI disorders and endoscopy. ELEVIEW is manufactured by Cosmo Technologies Ltd. in Dublin, Ireland and distributed by Pendopharm in Canada.
- SynthonmajorPartnership for GLATECT (glatiramer acetate for injection) launch in Canada for treatment of relapsing-remitting multiple sclerosis. Synthon is an international pharma company headquartered in the Netherlands with products approved in over 90 countries.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Pendopharm competitors and assessment
Company assessmentDirect peers
- Knight Therapeutics: Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products in Canada and select international markets. Highly comparable business model to Pendopharm with focus on specialty therapeutic areas and exclusive distribution agreements.
- HLS Therapeutics: Canadian specialty pharmaceutical company focused on acquiring and commercializing late-stage products for the North American market. Comparable specialty pharma distribution model with similar therapeutic focus areas including CNS and cardiology.
- Cipher Pharmaceuticals: Canadian specialty pharmaceutical company that commercializes specialty products through licensing and distribution partnerships. Directly comparable to Pendopharm in business model, therapeutic focus, and Canadian market focus.
- Acerus Pharmaceuticals: Canadian specialty pharmaceutical company focused on commercializing novel prescription products. Similar size and Canadian market focus with licensing-driven business model.
- Medison Pharma: Canadian-headquartered specialty pharma company that provides commercial access for innovative therapies in Canada and Israel. Closely comparable in-licensing and distribution model focused on specialty therapeutic areas.
Broad incumbents
- Bausch Health (formerly Valeant Pharmaceuticals): Headquartered in Canada, Bausch Health is a large diversified specialty pharmaceutical company with significant Canadian operations. Comparable as a major Canadian pharma incumbent though much larger and broader in scope than Pendopharm.
- AbbVie Canada: Major global pharmaceutical company with significant Canadian specialty pharma operations across immunology, neuroscience, and other therapeutic areas. Competes with Pendopharm's specialty portfolio offerings in Canada.
- Takeda Canada: Canadian subsidiary of global pharma major Takeda, with strong specialty pharma presence in gastroenterology, neurology, and rare diseases. Directly overlaps with Pendopharm's core therapeutic areas.
Others
- Innomar Strategies (AmerisourceBergen): Canadian specialty pharma services company providing commercialization, distribution, and patient support services. Comparable as a Canadian specialty pharma ecosystem participant, though services-focused rather than product-focused.
Regional players
- JAMP Pharma Group: Canadian pharmaceutical company headquartered in Quebec (like Pendopharm) with broad generic and specialty pharmaceutical portfolio. Comparable Quebec-based Canadian pharma with similar market scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Pendopharm social profiles
Digital presencePendopharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pendopharm leadership team
Management profileNumber of profiles
Profiles2 records
Pendopharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pendopharm M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pendopharm
What does Pendopharm do?
Pendopharm develops, in-licenses and commercializes specialty pharmaceutical products in Canada across four core therapeutic areas: gastroenterology, sports medicine & orthopedics, neurology, and cardiology. Its portfolio of more than 40 specialty products includes branded prescription drugs (Yorvipath, GLATECT, Octasa, IBAVYR), viscosupplementation treatments (Cingal, Monovisc, Orthovisc, SportVis), endoscopic procedural products (ELEVIEW), pediatric formulations, and consumer oral-care brands. The company secures exclusive Canadian distribution rights from international innovators and manages regulatory approval, market access, and commercialization.
Is Pendopharm a public or private company?
Pendopharm is a private company. It is classified as corporate owned and is currently operating.
When was Pendopharm founded?
Pendopharm was founded in 2010. It employs 1,001 to 5,000 people.
Where is Pendopharm based?
Pendopharm is headquartered in Montreal, Canada, in the North America region.
How does Pendopharm make money?
Two revenue lines are on record. Specialty Pharmaceutical Product Sales are the primary driver. The others are exclusive Distribution Agreements.
Who are Pendopharm's main competitors?
Direct peers on record are Knight Therapeutics, HLS Therapeutics, Cipher Pharmaceuticals, Acerus Pharmaceuticals and Medison Pharma. Broad incumbents are Bausch Health (formerly Valeant Pharmaceuticals), AbbVie Canada and Takeda Canada. Innomar Strategies (AmerisourceBergen) is listed as an others. JAMP Pharma Group is listed as a regional player.
Does Pendopharm have an API?
No public API is recorded for Pendopharm.
What industry is Pendopharm in?
Pendopharm's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.